BRIEF published on 11/21/2025 at 15:30, 9 months 20 days ago Le groupe Vanguard dévoile sa participation dans American Axle & Manufacturing Groupe Vanguard Code De Prise De Contrôle Situation Financière Information Sur Les Valeurs Mobilières Essieu Américain
BRIEF published on 11/21/2025 at 15:29, 9 months 20 days ago The Vanguard Group, Inc.: Disclosure on Avadel Pharmaceuticals Ordinary Shares Form 8.3 Disclosure Vanguard Group Avadel Pharmaceuticals
BRIEF published on 11/21/2025 at 15:29, 9 months 20 days ago The Vanguard Group, Inc. : Informations sur Avadel Pharmaceuticals Groupe Vanguard Actions Ordinaires Divulgation Formulaire 8.3 Avadel Pharmaceuticals
BRIEF published on 11/21/2025 at 15:28, 9 months 20 days ago The Vanguard Group Discloses Position in Mural Oncology Form 8.3 Irish Takeover Panel Securities Disclosure Vanguard Group Mural Oncology
BRIEF published on 11/21/2025 at 15:28, 9 months 20 days ago Le groupe Vanguard dévoile sa position dans le domaine de l'oncologie murale Groupe Vanguard Formulaire 8.3 Information Sur Les Valeurs Mobilières Oncologie Murale Panel Irlandais Des OPA
BRIEF published on 11/21/2025 at 15:26, 9 months 20 days ago The Vanguard Group Discloses Position in Just Group plc The Vanguard Group Takeover Code Securities Disclosure Shareholding Just Group
BRIEF published on 11/21/2025 at 15:26, 9 months 20 days ago Le groupe Vanguard révèle sa participation dans Just Group plc Actionnariat Code De Prise De Contrôle Le Groupe Vanguard Information Sur Les Valeurs Mobilières Groupe Just
BRIEF published on 11/21/2025 at 15:25, 9 months 20 days ago Vanguard Group Discloses Interests in International Personal Finance Form 8.3 Takeover Code Securities Disclosure Vanguard Group International Personal Finance
BRIEF published on 11/21/2025 at 15:25, 9 months 20 days ago Le groupe Vanguard révèle ses intérêts dans le secteur de la finance personnelle internationale. Groupe Vanguard Code De Prise De Contrôle Formulaire 8.3 Information Sur Les Valeurs Mobilières Finances Personnelles Internationales
BRIEF published on 11/21/2025 at 15:25, 9 months 20 days ago XRG Obtains Full Approvals for Covestro AG Acquisition Global Expansion Regulatory Approvals Covestro AG XRG Acquisition Chemicals Sector
Published on 09/11/2026 at 17:00, 2 hours 42 minutes ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/11/2026 at 17:00, 2 hours 42 minutes ago Critical Elements sélectionné pour inclusion dans le prospectus du sommet Canadien de l'investissement, mettant le projet en valeur auprès d'investisseurs mondiaux de premier plan
Published on 09/11/2026 at 15:25, 4 hours 17 minutes ago Revolve Signs Agreement to Acquire 9.6 MW Operating Wind Project in the US and Secures Project-Level Debt Financing with EDC and Vancity
Published on 09/11/2026 at 15:00, 4 hours 42 minutes ago Regentis Biomaterials Reports First Half 2026 Financial Results and Provides Corporate Update
Published on 09/11/2026 at 14:30, 5 hours 12 minutes ago AIAI Holdings Enters into Extended Lock-up Agreements to Protect Long-Term Stockholder Value
Published on 09/11/2026 at 18:15, 1 hour 27 minutes ago CGTN: How BRICS creates new opportunities for Global South development
Published on 09/11/2026 at 18:00, 1 hour 42 minutes ago ROCTOOL: INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 09/11/2026 at 18:00, 1 hour 42 minutes ago ROCTOOL: INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 09/11/2026 at 07:00, 12 hours 42 minutes ago Transparantiekennisgeving van Baltisse Groep
Published on 09/11/2026 at 07:00, 12 hours 42 minutes ago Transparency notification by Baltisse Group
Published on 09/11/2026 at 07:00, 12 hours 42 minutes ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 12 hours 42 minutes ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
